In September 2022, RainMed Medical was invited to participate in the 2022 China Medical Device Outbound Conference hosted by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and VBDATA.CN. At the conference, RainMed Medical comprehensively introduced and displayed its original products -- caIMR system, the world's first non-interventional IMR measurement product; caFFR system, the first independently developed angiography-derived  FFR product in China; FlashBot vascular interventional surgery robot to be launched later covering the whole process of diagnosis and treatment and so on, which can provide a comprehensive evaluation from epicardial coronary artery to coronary microcirculation and accurately guide the treatment of coronary heart disease. RainMed Medical was also awarded the "2022 Most Innovative Outbound Medical Devices", bringing new solutions to world's difficult problems with local innovation in China.

The 2022 China Medical Device Outbound Conference focuses on the export of medical devices. With "trade relations" as the core, it focuses on three parts: "Wind rise, Wave break and Navigate". It is a brand conference with global influence, which is based on Chinese enterprises and integrates international trade cooperation, pharmaceutical industry exchange, institutional technology exchange and enterprise product display under the "Belt and Road" construction plate.

At the meeting, RainMed conducted in-depth discussions on the innovation and upgrading of coronary functional diagnostic products, cross-border trade, international layout and other topics from a global perspective. RainMed Medical, founded in 2014, is committed to becoming world's leading vascular interventional robotics company. caFFR calculates fractional flow reserve FFR based on two angiograms without pressure guide wire or hyperemic agents. It can provide functional indicators during surgery to accurately evaluate whether coronary artery stenosis induces myocardial ischemia. It provides a safe, efficient, accurate and simple solution for cardiovascular diagnosis. Designed and produced by a Chinese local team, caFFR will further demonstrate the infinite charm of China’s smart manufacturing on the global stage for hospitals and medical imaging centers at all levels.

The traditional guide wire-based IMR detection technology requires the use of pressure guidewire, hyperemic agents and repeated injection of SPSS, which is complicated and has high surgical risk, and is difficult to be used daily. However, RainMed’s caIMR system has solved the difficult problem of guide wire-based IMR technology in a pioneering way, allowing rapid evaluation before and after PCI, and providing an opportunity for large-scale coronary microcirculatory functional diagnosis. Research shows that caIMR’s accuracy of online and offline measurement was as high as 93.81% and 94.69% respectively. Compared with the guide wire IMR, it has high sensitivity and speciality.

RainMed Medical has excellent ability of scientific research transformation and commercial landing. The series of products developed by the company have been widely recognized by experts and scholars in the industry. At the same time, RainMed Medical has successfully established two marketing centers at home and abroad, and formed marketing teams of more than 100 people. Up to now, RainMed Medical's commercial network has covered 29 provinces and autonomous regions in China. It has also built a distribution network in Europe, Africa, and Southeast Asia. As a Chinese local innovative enterprise, RainMed has a thoughtful international strategic layout. In the future, RainMed will continue to be in line with the international market based on innovation and research and development, and achieve the long-term goals to international marketing and help promote industrial upgrading in China.

"Only by staying true to the original aspiration, maintaining innovation and being calm can we ensure the continuous originality of the enterprise and show the charm of Chinese medical devices on the international stage." Just as chairman Yunfei Huo hopes: RainMed Medical will adhere to medical innovation, master core technologies, promote China's original research and development of more original medical devices, show the charm of China's creation on the international stage, and make China's "smart manufacturing" benefit patients with vascular disease around the world.